Edesa Biotech reports Q1 FY2025 net loss of $1.6M; raises $15M in private placement

Edesa Biotech, Inc.

Net loss of $1.6M ($0.48/share) compared to $1.7M ($0.54/share) in prior year quarter.
R&D expenses rose to $1.0M (from $0.7M) on increased manufacturing costs for paridiprubart.
Cash at Dec 31, 2024 was $1.6M; subsequent $15M preferred/common private placement closed.
Company plans IND for EB06 (anti-CXCL10) in vitiligo Phase 2; FDA submission mid-2025.
EB05 (paridiprubart) ARDS study fully funded by U.S. government; top-line vitiligo data expected within 12-18 months post clearance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.